IMPORTANT NOTICE: MedTrace’s products are not currently cleared for routine use in any markets, including both the US and Europe. In the US, 15O-water is currently under investigation as an investigational drug in a Phase 3 clinical trial. In Europe, its use is in compliance with approvals granted by national drug authorities, in accordance with the specific legislation of each member state.

Perfusion imaging provides medical professionals with a functional understanding of the organs blood supply inside the patient.

MedTrace is developing a solution that will help healthcare providers diagnose patients more accurately and quickly.

Our solution allows for absolute blood flow quantification based upon the PET tracer 15O-water, which has long been acknowledged as the gold standard tracer for non-invasive blood flow quantification.

Our innovative solution is intended to making 15O-water practically available right next to the PET scanner connected to an onsite cyclotron, with a software package to quantify the myocardial blood flow and perfusion.

Based in Denmark with office in US, MedTrace already installed systems in Denmark, Sweden, and US for investigational research.

Press releases


MedTrace Obtains CE Mark for Patient Kits as Medical Devices


Ann Kristin Led Is Appointed as CEO of MedTrace


MedTrace Raises 18 Million Euro for Its Phase III Trial

15O-water is a very short-lived radioactive version of regular water, in which the oxygen atom has been replaced by oxygen-15, a positron-emitting isotope.

MedTrace has developed a solution with an automated chemistry system for manufacturing and infusion of 15O-water and an analytical software platform for 15O-water PET.

MedTrace’s team is growing quickly, and we are looking for people who are excited about cutting-edge technology that can help patients be diagnosed accurately and efficiently.

”The availability of a reliable approved system for bedside production of 15O-water could change 15O-water PET from an exotic research tool to a clinical workhorse”

Rune Wiik Kristensen, MedTrace Pharma